Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
Last trade$5.49
Day change-$0.21 (-3.68%)
Day range$5.47 – $5.69
Volume462,173
Market cap$556M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$555.71M
Price / earnings
—
Price / book
2.45×
Price / sales
238.3×
EV / sales
138.57×
EV / EBITDA
-2.89×
Profitability
Earnings per share
-$1.11
Return on assets
-41.2%
Return on equity
-47.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.45×
Quick ratio
12.45×
Cash ratio
12.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$93.48M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$519K
$1.01M
$494K
$310K
$429K
$618K
$556K
$536K
Cost of revenue
$126K
$233K
$114K
$91K
$123K
$148K
$207K
$208K
Gross profit
$393K
$776K
$380K
$219K
$306K
$470K
$349K
$328K
Selling, general and administrative
$8.9M
$8.4M
$6.93M
$9.67M
$5.76M
$5.01M
$5.67M
$8.53M
Research and development
$21.33M
$23.37M
$17.46M
$19.51M
$16.81M
$16.34M
$16.46M
$13.32M
Total operating expenses
$30.23M
$31.77M
$24.39M
$29.18M
$22.57M
$21.35M
$22.13M
$21.85M
Operating income
-$29.84M
-$31M
-$24.01M
-$28.97M
-$22.27M
-$20.88M
-$21.78M
-$21.52M
Interest expense
-$17K
-$131K
-$27K
-$10K
-$15K
-$22K
-$26K
-$473K
Income before taxes
-$27.1M
-$28.78M
-$22.41M
-$29.02M
-$22.21M
-$21.06M
-$21.93M
-$19.2M
Income taxes
-$272K
$0
$492K
$0
$0
$0
$0
$0
Net income
-$26.83M
-$28.78M
-$22.9M
-$29.02M
-$22.21M
-$21.06M
-$21.93M
-$19.2M
Net income attributable to common shareholders
-$26.83M
-$29.09M
-$23.02M
-$29.2M
-$22.24M
-$20.83M
-$21.86M
-$19.38M
EBITDA
-$29.35M
-$30.53M
-$23.58M
-$28.54M
-$21.85M
-$20.47M
-$21.38M
-$21.12M
Basic earnings per share
-$0.28
-$0.30
-$0.28
-$0.74
-$0.62
-$0.58
-$0.61
-$0.82
Diluted earnings per share
-$0.28
-$0.30
-$0.28
-$0.74
-$0.62
-$0.58
-$0.61
-$0.82
Recent news
Company coverage with links to the original publishers.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Anteris Technologies announced positive 30-day clinical and hemodynamic outcomes for its Medium-size DurAVR Transcatheter Heart Valve in 22 severe aortic stenosis patients. The valve demonstrated single-digit mean gradients, large effective orifice areas, no moderate or severe paravalvular leaks, and zero valve-related mortality. The company is advancing its PARADIGM pivotal trial, a randomized controlled study comparing DurAVR to commercially available TAVR devices in approximately 1,000 patients.
Anteris Technologies announced that it will present first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve at the TCT 2026 conference in San Diego. The presentation will showcase results from the ongoing EMBARK study, which has treated over 130 patients with the DurAVR THV since 2021. The company will also feature a live case demonstration of the biomimetic valve technology.
Anteris Technologies announced it has received full regulatory clearance from Germany's BfArM to initiate the PARADIGM Trial for its DurAVR Transcatheter Heart Valve in patients with severe aortic stenosis. The clearance enables patient recruitment at leading German centers and strengthens the trial's European expansion, as Germany represents Europe's largest TAVR market with extensive clinical infrastructure.
Anteris Technologies Global Corp. announced that Vice Chairman and CEO Wayne Paterson will present at three major healthcare conferences in September 2026: Cantor Global Healthcare Conference (Sept 9), Wells Fargo 21st Annual Healthcare Conference (Sept 10), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14). The company is showcasing its DurAVR® Transcatheter Heart Valve, a biomimetic device designed to treat aortic stenosis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.